OKYO Pharma
limits of current standard of care | OKYO Pharma
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
7 of 25
Related slides by other companies
Nuvalent
Investor Presentation
January 2024
potential best in class profile for opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc mutation disease current soc of disease demonstrated activity where current available therapies have failed opportunity to supplant standard of care with a differentiated clinical activity observed in heavily patients with who likely exhausted all available therapies including after or with resistance mutations with history of metastasis including intracranial responses to address combined medical needs mutation coverage activity avoiding off target adverse events opportunity to drive deep durable responses favorable preliminary safety consistent with selective sparing design sources sales and forecasts accessed lin precision and lung cancer a | Nuvalent
Mednow
Investor Presentation
May 2022
investment highlights forecasts show strong growth calendar full year forecast calendar full year forecast revenue revenue gross margin gross margin negative adjusted margin million adjusted active patients define with active in last months active patients define with active in last months | Mednow
Bluejay
Investor Presentation
December 2023
current sepsis assessment methods are complex and slow floor a | Bluejay
Nuvalent
Investor Presentation
January 2024
potential best in class profile for opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc mutation disease current soc of disease demonstrated activity where current available therapies have failed opportunity to supplant standard of care with a differentiated clinical activity observed in heavily patients with who likely exhausted all available therapies including after or with resistance mutations with history of metastasis including intracranial responses to address combined medical needs mutation coverage activity avoiding off target adverse events opportunity to drive deep durable responses favorable preliminary safety consistent with selective sparing design sources sales and forecasts accessed lin precision and lung cancer a | Nuvalent
Other recent decks by OKYO Pharma
See all presentations (2 decks)
Shareholder Engagement
March 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights